QIAGEN has received FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its U.S. syndromic testing portfolio for gastrointestinal infections. The panel rapidly detects five key bacterial pathogens—Campylobacter, Salmonella, STEC, Shigella, and Yersinia enterocolitica—in about one hour, supporting fast outpatient diagnostics. This is QIAGEN’s second FDA-cleared QIAstat-Dx panel in 2025 and complements their existing bacterial and viral GI panels, offering laboratories targeted, flexible solutions for diverse clinical settings.
Trending
- ‘Tremendous implications’: Hospital affiliation linked to higher-cost care (Healio)
- Omada Health Launches AI-Powered Meal Map to Transform Nutrition for Cardiometabolic Patients (HIT Consultant)
- 10 Must-Read Posts in GI Oncology This Week (OncoDaily)
- SCA Health expands GI footprint, physician network in 2025 (Becker’s GI & Endoscopy)
- 7 key numbers on the state of GI in 2025 (Becker’s GI & Endoscopy)
- White House Unveils ‘TrumpRx’ Drug-Buying Site and a Pfizer Pricing Deal (The Wall Street Journal)
- CADe for Colonoscopy: Positive and Negative Takeaways From Largest Real-World Study (GI & Endoscopy News)
- FDA OKs Tremfya for Ulcerative Colitis (GI & Hepatology News)